Key Points
- Investigate environmental, clinical, and genetic factors associated with clopidogrel resistance in patients with cardiovascular disease.
- Evaluated 270 cardiovascular disease patients in Jordan for clopidogrel resistance using the Multiplate analyzer for platelet aggregation.
- Genotyped CYP2C19*2 and PON1 Q192R polymorphisms using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis.
- Clopidogrel resistance occurred in approximately 32% of patients and was significantly associated with female gender, concomitant calcium channel blocker use, and low HDL levels (p < 0.05).
- Presence of the CYP2C19*2 allele demonstrated a strong association with clopidogrel resistance (p < 0.001).
- No significant associations were identified for the PON1 Q192R polymorphism, age, diabetes, hypertension, smoking, or aspirin use (p > 0.05).
Structured PICO
PPopulation270 cardiovascular disease patients from Jordan
IInterventionClopidogrel therapy
OOutcomeClopidogrel resistance determined through platelet aggregation analysis using the Multiplate analyzersurrogate
Clopidogrel resistance is common (32%) among Jordanian cardiovascular patients and is significantly associated with female gender, calcium channel blocker use, low HDL, and the CYP2C19*2 polymorphism.